TearLab Corp CEO Buys $240,100 in Stock (TEAR)
TearLab Corp (NASDAQ:TEAR) CEO Elias Vamvakas acquired 70,000 shares of TearLab Corp stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average price of $3.43 per share, with a total value of $240,100.00. Following the completion of the purchase, the chief executive officer now directly owns 271,404 shares of the company’s stock, valued at approximately $930,916. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
TEAR has been the subject of a number of recent research reports. Analysts at Canaccord Genuity cut their price target on shares of TearLab Corp from $10.00 to $8.00 in a research note on Friday, August 8th. Analysts at Feltl & Co. downgraded shares of TearLab Corp from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 8th.
TearLab Corp (NASDAQ:TEAR) traded down 1.49% during mid-day trading on Wednesday, hitting $3.31. The stock had a trading volume of 271,765 shares. TearLab Corp has a 52 week low of $3.30 and a 52 week high of $13.78. The stock’s 50-day moving average is $4.69 and its 200-day moving average is $5.57. The company’s market cap is $111.2 million.
TearLab Corp (NASDAQ:TEAR) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.01. The company had revenue of $9.20 million for the quarter, compared to the consensus estimate of $5.12 million. The company’s revenue for the quarter was up 53.3% on a year-over-year basis. On average, analysts predict that TearLab Corp will post $-0.67 earnings per share for the current fiscal year.
TearLab Corp. is an in-vitro diagnostic company. The Company is commercializing a tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.